search
Back to results

CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial

Primary Purpose

Chronic Pain, Back Pain, Neck Pain

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Tizanidine
MI-Opioid Taper
Placebo
Enhanced Usual Care
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Pain

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults aged 18-64 scheduled for elective spine surgery for lumbar or cervical degenerative disease (e.g. lumbar or cervical disc herniation, lumbar or cervical spinal stenosis, lumbar or cervical degenerative spondylolisthesis, lumbar or cervical disc degeneration, or degenerative cervical myelopathy including cervical spondylotic myelopathy). Preoperative long-term opioid use (Defined as ≥ 90-day duration of use in the 4 months preceding surgery either via self-report or state PDMP. Participants must report at least one of the following on preoperative assessments: Current Opioid Misuse Measure (COMM) score greater than or equal to 9 Answering "Yes" to any of the following items on the modified Brief Pain Inventory (BPI)1) Over the past 24 hours have you needed to take your pain medication to help you sleep; 2)Have you taken any pain medications for any reason other than your pain, such as to reduce anxiety or improve mood? 3) Have you taken more pain medication than was prescribed to you in the past 24 hours? Score of greater than or equal to 2 on any Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS-1) item Positive Alcohol Use Disorders Identification Test (AUDIT-C) score (greater than or equal to 4 for men, greater than or equal to 3 for women) Elevated opioid use 14 days after surgery compared to baseline daily OME Defined as average daily OME assessed over 3 days 1 week before surgery compared to average daily OME reported on postoperative days 12 to 14 to account for as-needed dosing and day-to-day variations in opioid use. English-speaking Ability and willingness to complete online assessments Exclusion Criteria: Infection, tumor, or fracture at the operative site Allergy or intolerance to tizanidine Current use of tizanidine Renal impairment Hepatic impairment including cirrhosis or elevated enzymes Concurrent use of other α2-adrenergic agonists, skeletal muscle relaxants Concurrent use of: fluvoxamine, ciprofloxacin,zileuton, fluoroquinolones, antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, oral contraceptive pills, acyclovir, ticlopidine, and fexinidazole Pre-existing hypotension, sedation, dizziness, severe respiratory insufficiency. Opioid Use Disorder Suicidality as assessed by the Patient Health Questionnaire-9 (PHQ-9) Question 9 score ≥ 1 Pregnancy, breastfeeding, or planning to conceive Cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) Participating in another clinical trial with an active treatment arm

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Arm Label

    MI-Opioid Taper and tizanidine

    MI-Opioid Taper and placebo

    Enhanced Usual Care

    Arm Description

    Outcomes

    Primary Outcome Measures

    Time to baseline opioid use
    Defined as the 1st of 2 consecutive reports of return to preoperative daily OME use or lower on the modified BPI.Preoperative daily OME use is defined as average daily OME assessed over 3 days, on days 7 to 9 before surgery.

    Secondary Outcome Measures

    Full Information

    First Posted
    August 30, 2023
    Last Updated
    September 7, 2023
    Sponsor
    Stanford University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06027099
    Brief Title
    CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial
    Official Title
    Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 2024 (Anticipated)
    Primary Completion Date
    January 2028 (Anticipated)
    Study Completion Date
    July 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Stanford University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Three-arm randomized controlled trial, of Motivational Interviewing and guided Opioid Tapering support (MI-Opioid Taper) and tizanidine vs. MI-Opioid Taper and placebo vs. enhanced usual care to promote postoperative opioid cessation and pain cessation and reduce the incidence of postoperative opioid misuse among patients undergoing spine surgery.
    Detailed Description
    In this Type 1 hybrid effectiveness-implementation three-arm parallel RCT, 375 patients with preoperative LTOU undergoing spine surgery will be recruited across 4 sites (Stanford, Harvard, Wake Forest, U. of Kansas) and randomized to 1 of 3 groups (MI-Opioid Taper and tizanidine, MI-Opioid Taper and placebo, enhanced usual care) and followed for 12 months. The primary outcome is time to baseline opioid use. Secondary outcomes are time to opioid cessation, opioid dispensing cessation, pain cessation, and risk of postoperative opioid misuse. We will examine motivation for change, change talk, and reduction in pain as mediators of treatment effects and characterize treatment interactions with participant attributes in predicting both treatment engagement and efficacy. A mixed-methods evaluation using the RE-AIM framework will explore barriers and facilitators to future larger-scale implementation of MI-Opioid Taper. The project will address the unmet needs of patients on long-term opioid use presenting for surgery in need of precision postoperative pain care to minimize opioid-related harms.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Pain, Back Pain, Neck Pain, Opioid Misuse

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    375 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    MI-Opioid Taper and tizanidine
    Arm Type
    Experimental
    Arm Title
    MI-Opioid Taper and placebo
    Arm Type
    Experimental
    Arm Title
    Enhanced Usual Care
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Tizanidine
    Intervention Description
    Tizanidine 2mg three times a day for 5 weeks after surgery
    Intervention Type
    Behavioral
    Intervention Name(s)
    MI-Opioid Taper
    Intervention Description
    Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    1 tablet three times a day for 5 weeks after surgery
    Intervention Type
    Behavioral
    Intervention Name(s)
    Enhanced Usual Care
    Intervention Description
    Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide & Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
    Primary Outcome Measure Information:
    Title
    Time to baseline opioid use
    Description
    Defined as the 1st of 2 consecutive reports of return to preoperative daily OME use or lower on the modified BPI.Preoperative daily OME use is defined as average daily OME assessed over 3 days, on days 7 to 9 before surgery.
    Time Frame
    Assessed after surgery up to 1 year after surgery

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    64 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults aged 18-64 scheduled for elective spine surgery for lumbar or cervical degenerative disease (e.g. lumbar or cervical disc herniation, lumbar or cervical spinal stenosis, lumbar or cervical degenerative spondylolisthesis, lumbar or cervical disc degeneration, or degenerative cervical myelopathy including cervical spondylotic myelopathy). Preoperative long-term opioid use (Defined as ≥ 90-day duration of use in the 4 months preceding surgery either via self-report or state PDMP. Participants must report at least one of the following on preoperative assessments: Current Opioid Misuse Measure (COMM) score greater than or equal to 9 Answering "Yes" to any of the following items on the modified Brief Pain Inventory (BPI)1) Over the past 24 hours have you needed to take your pain medication to help you sleep; 2)Have you taken any pain medications for any reason other than your pain, such as to reduce anxiety or improve mood? 3) Have you taken more pain medication than was prescribed to you in the past 24 hours? Score of greater than or equal to 2 on any Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS-1) item Positive Alcohol Use Disorders Identification Test (AUDIT-C) score (greater than or equal to 4 for men, greater than or equal to 3 for women) Elevated opioid use 14 days after surgery compared to baseline daily OME Defined as average daily OME assessed over 3 days 1 week before surgery compared to average daily OME reported on postoperative days 12 to 14 to account for as-needed dosing and day-to-day variations in opioid use. English-speaking Ability and willingness to complete online assessments Exclusion Criteria: Infection, tumor, or fracture at the operative site Allergy or intolerance to tizanidine Current use of tizanidine Renal impairment Hepatic impairment including cirrhosis or elevated enzymes Concurrent use of other α2-adrenergic agonists, skeletal muscle relaxants Concurrent use of: fluvoxamine, ciprofloxacin,zileuton, fluoroquinolones, antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, oral contraceptive pills, acyclovir, ticlopidine, and fexinidazole Pre-existing hypotension, sedation, dizziness, severe respiratory insufficiency. Opioid Use Disorder Suicidality as assessed by the Patient Health Questionnaire-9 (PHQ-9) Question 9 score ≥ 1 Pregnancy, breastfeeding, or planning to conceive Cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) Participating in another clinical trial with an active treatment arm

    12. IPD Sharing Statement

    Learn more about this trial

    CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial

    We'll reach out to this number within 24 hrs